Researchers from The Pirbright Institute collaborated with the University of Oxford and the National Institutes of Health, USA, to show that S-FLU, a universal flu vaccine candidate, induces different immune responses in pigs compared to ferrets, raising the possibility that the ferrets may not give the whole picture and that pigs may more faithfully represent human influenza disease. The team also identified a type of T cell in pigs for the first time, which are able to rapidly help fight respiratory infections.
The S-FLU aerosol vaccine, developed by Alain Townsend at Oxford, is a weakened strain of flu virus which is designed to trigger a response from T cells that are able to react to multiple strains of flu. This differs from conventional flu vaccines which activate antibodies that only respond to the strain contained in the vaccine.
The research, published in the Journal of Immunology, demonstrated that when pigs received the S-FLU aerosol vaccine, the newly identified T cells (called tissue-resident memory T cells) were activated when challenged with a flu virus of a different strain. Disease severity was also reduced, but the amount of virus remained the same. However, when S-FLU was administered to ferrets, the viral replication was reduced, as was the amount of virus that was transmitted to other animals.
This striking difference in response to the exact same vaccine raises the question whether the ferret, an animal model that is considered gold standard for influenza research, provides results which are transferrable to humans. Pigs provide a model that is more similar in size, naturally infected by influenza viruses and with a very similar respiratory system to humans.
The group’s discovery of tissue-resident memory T cell activation in pigs also brings them closer to understanding how influenza is combatted in the lung. Dr Elma Tchilian, Head of the Mucosal Immunology group at Pirbright, said: “The identification of these T cells will allow us to establish how best to induce and maintain them in the lung, and help us make more effective vaccines against influenza and other respiratory diseases in both livestock and humans”.
The results also show that targeting the lower respiratory tract with aerosol vaccination in pigs may be more effective than other routes of immunization in preventing severe disease, which provides promising evidence that this method of vaccination could be successful in humans too.
Notes to editors
There are many strains of influenza, each of which have different outer coats and are able to rapidly mutate, fooling the immune system and rendering the antibodies produced to one particular strain ineffective against other strains. This presents a major obstacle when engineering vaccines that are able to act against multiple flu stains, as the more conventional methods of producing vaccines rely on antibody responses.
This work was supported by Bill & Melinda Gates Foundation Grant OPP1148786, Biotechnology and Biological Sciences Research Council (BBSRC) Grant BBS/E/I/00007031, BBSRC Strategic Longer and Larger Grant BB/L001330/1, and the Townsend-Jeantet Prize Charitable Trust.
About The Pirbright Institute
The Pirbright Institute is a world leading centre of excellence in research and surveillance of virus diseases of farm animals and viruses that spread from animals to humans. Based in the UK and receiving strategic funding from the Biotechnology and Biological Sciences Research Council (BBSRC), the Institute works to enhance capability to contain, control and eliminate these economically and medically important diseases through highly innovative fundamental and applied bioscience.
With an annual income of nearly £26.1 million from grants and commercial activity, and a total of £5 million strategic investment from BBSRC during 2016-2017, the Institute contributes to global food security and health, improving quality of life for animals and people.
For more information about The Pirbright Institute see: www.pirbright.ac.uk
The Biotechnology and Biological Sciences Research Council (BBSRC) is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
More information about BBSRC, our science and our impact: www.bbsrc.ac.uk
More information about BBSRC strategically funded institutes: www.bbsrc.ac.uk/institutes